News Archive - Navrogen : Navrogen

March 26, 2025

Navrogen Inc Announces Publication and Presentation at the American Association for Cancer Research (AACR) Annual Meeting of a Novel Antibody Engineering Platform

Cheyney, PA, March 26, 2025 – Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for cancer, announces today a publication describing new criteria for monoclonal antibody (mAb) and...

April 4, 2024

Navrogen Presents Its Anti-CD20 Antibody NAV-006 and ICAM-1 Refractory Antibody-Drug Conjugate Platform at the 2024 American Association for Cancer Research Conference

Cheyney, PA, April 4, 2024 — Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will present preclinical data on its next-generation anti-CD20 antibody, NAV-006, and...

May 18, 2023

Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers

Cheyney, PA, May 18, 2023 — Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announces today a publication describing new criteria for antibody-drug conjugate...

April 12, 2023

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Meeting

NAV-001 and NAV-003 both target mesothelin, a cell surface protein over-expressed on various malignancies. Certain ADCs and therapeutic antibodies targeting mesothelin are negatively affected by Humoral Immuno-Oncology (HIO) factors...

March 27, 2023

Navrogen and the National Cancer Institute Establish Collaboration to Study the Impact of Immunosuppressive Factor CA125 on Rituximab Effectiveness

Navrogen has established a research collaboration with the U.S. National Cancer Institute to study the potential role of Cancer Antigen-125 (CA125) in causing immunosuppression in patients with hematologic cancers,...

November 7, 2022

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Navrogen announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes...